ProCE Banner Activity

CASSIOPEIA Part 2: Daratumumab Maintenance or Observation After Treatment With VTd or D-VTd and ASCT in Newly Diagnosed MM

Slideset Download
Conference Coverage
In patients with newly diagnosed MM, compared with observation, daratumumab maintenance significantly improved PFS and depth of response following induction/consolidation therapy.

Released: June 14, 2021

Expiration: June 13, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme